Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future

Michael Raymond Binder

doi:doi:10.11648/j.ajcem.20210905.18

| Peer-Reviewed

Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future

Michael Raymond Binder

Published in American Journal of Clinical and Experimental Medicine (Volume 9, Issue 5)

Received: 28 September 2021 Accepted: 18 October 2021 Published: 28 October 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

After more than a century of scientific study and philosophical debate, the neurobiology of psychiatric disorders is still unclear. However, an emerging hypothesis contends that psychiatric and related functional symptoms are rooted in an inherent hyperexcitability of the neurological system. Particularly under the influence of stress, too many neurons fire for too long, resulting in circuit-specific psychiatric symptoms such as anxiety, depression, irritability, insomnia, inattention, and obsessional thinking as well as various physical symptoms that have no identifiable organic cause, such as migraine headache, fibromyalgia, irritable bowel, and chronic pain. Based on this hypothesis, anticonvulsant drugs, which could more aptly be called “Neuroregulators” because of their proposed mechanism of action, should have emerged as the drugs of choice for most of these disorders. Yet the use of anticonvulsants, at least for psychiatric disorders, dwindles in comparison to antidepressants, antipsychotics, psychostimulants, and sedative hypnotics. This article addresses the dearth of anticonvulsant drug use and the hypothetical reasons that several other classes of drugs continue to be used ahead of anticonvulsants despite the expanding base of evidence in support of the neuronal hyperexcitability hypothesis. The article will also propose new ways that anticonvulsants could be used to optimize their effectiveness for the wide range of disorders they should be able to treat, and it will discuss the means by which anticonvulsants could, in theory, be used prophylactically to prevent the development of an equally wide range of general medical conditions, including diabetes, high blood pressure, cardiovascular disease, autoimmune disease, dementia, and cancer.

Published in	American Journal of Clinical and Experimental Medicine (Volume 9, Issue 5)
DOI	10.11648/j.ajcem.20210905.18
Page(s)	174-182
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Anticonvulsants, Bipolar Spectrum Disorders, Neuronal Hyperexcitability, Ionchannelopathies, Preventive Medicine

References

[1]	Binder MR. The multi-circuit neuronal hyperexcitability hypothesis of psychiatric disorders. AJCEM 2019; 7 (1): 12-30.
[2]	Grunze HCR. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci 2008; 10 (1): 77-89.
[3]	McGovern PE, Zhang J, Tang J, et al. Fermented beverages of pre- and proto-historic China. PNAS 2004; 101 (51): 17593-17598.
[4]	Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and epilepsy. Neurotherapeutics 2015; 12 (4): 747–768.
[5]	Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: ∆9-tetrahydrocannabinol, cannabidiol and ∆9-tetrahydrocannabivarin. British Journal of Pharmacology 2008; 153 (2): 199–215.
[6]	Silvestro S, Mammana S, Cavalli E, Bramanti P, Amazon E. Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trials. Molecules 2019; 24 (8): 1459.
[7]	Pearce JMS. Bromide, the first effective antiepileptic agent. Journal of Neurology, Neurosurgery & Psychiatry 2001; 72 (3).
[8]	Hillhouse TM and Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015; 23 (1): 1-21.
[9]	Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK. Antidepressants: from MAOIs to SSRIs and more. Indian Journal of Psychiatry 2011; 53 (2): 180-182.
[10]	Kreston R. (2016) The psychic energizer! the serendipitous discovery of the first antidepressant - Body Horrors. http://blogs.discovermagazine.com/bodyhorrors/2016/01/27/2 081/. (Accessed 10/2/18).
[11]	Hirschfeld, R. History and evolution of the monoamine hypothesis of depression. Journal of Clinical Psychiatry 2000; 61 (6): 4-6.
[12]	Yizhar O, Fenno LE, Prigge M, et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011; 477: 171-178.
[13]	Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6 (4): 312-24.
[14]	Singer HS, Minzer K. Neurobiology of Tourette's syndrome: concepts of neuroanatomic localization and neurochemical abnormalities. Brain Dev 2003; Suppl 1: S70-84.
[15]	Rubenstein JL, Merzenich, MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003; 2: 255–267.
[16]	Khedr EM, Elserogy Y, Fawzy M. Effect of psychotropic drugs on cortical excitability of patients with major depressive disorders: A transcranial magnetic stimulation study. Psychiatry Research 2020; 291: 113287.
[17]	Binder MR. Electrophysiology of seizure disorders may hold key to the pathophysiology of psychiatric disorders. AJCEM 2019; 7 (5): 103-110.
[18]	El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. Journal of Affective Disorders 2015; 184: 318-321.
[19]	Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disorders 2001; 5 (6).
[20]	Truman CJ, Goldberg JF, Ghaemi SN. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2007; 68 (10): 1472-1479.
[21]	Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-induced mania in bipolar patients: Identification of risk factors. J Clin Psychiatry 2001; 62 (4): 249-255.
[22]	Yamaguchi Y, Kimoto S, Nagahama T, Kishimoto T. Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series. Neuropsychiatr Dis Treat 2018; 14: 2099-2104.
[23]	Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont) 2010; 7 (10): 14–18.
[24]	Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American J Psychiatry 2006; 163 (11): 1905-1917.
[25]	Amsterdam JD, Kim TT. Prior antidepressant treatment trials may predict a greater risk of depressive relapse during antidepressant maintenance therapy. Journal of Clinical Psychopharmacology 2019; 39 (4): 344-350.
[26]	Leykin Y, Amsterdam JD, DeRubeis RJ, et al. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. Journal of Consulting and Clinical Psychology 2007; 75 (2): 267–276.
[27]	Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addictive Behaviors 2019; 97: 111-121.
[28]	Jakobsen JC, Katakam KK, Schou A, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry 2017; 17 (58).
[29]	Davies JA. Mechanisms of action of antiepileptic drugs. Seizure 1995; 4 (4): 267-71.
[30]	Binder MR. Introducing the term “Neuroregulator” in psychiatry. AJCEM 2019; 7 (3): 66-70.
[31]	Gallagher RM, Mueller LL, Freitag FG. Divalproex sodium in the treatment of migraine and cluster headaches. J Am Osteopath Assoc 2002; 102 (2): 92.
[32]	Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41 (2): 119-28.
[33]	Perloff MD, Berlin RK, Gillette M, Petersile MJ, Kurowski D. Gabapentin in headache disorders: what is the evidence? Pain Med 2016; 17 (1): 162-71.
[34]	Kimos P, Biggs C, Mah J, et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain 2007; 127 (1-2): 151-160.
[35]	Bauer CA, Brozoski TJ. Effect of gabapentin on the sensation and impact of tinnitus. Laryngoscope 2006; 116 (5): 675-681.
[36]	White TL, Kent PF, Kurtz DB, Emko P. Effectiveness of gabapentin for treatment of burning mouth syndrome. Arch Otolaryngol Head Neck Surg 2004; 130 (6): 786-8.
[37]	Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007; 56 (9): 1218-25.
[38]	Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005; 15; 22 (10): 981-988.
[39]	Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a randomized controlled trial. Neurology. 2004; 63: 2104-2110.
[40]	Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews. 2005 (3). Art. No.: CD005452.
[41]	Uceyler N, Sommer C, Walitt B, Hauser W. Anticonvulsants for fibromyalgia 2017; 10: CD010782.
[42]	Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007; 56 (4): 1336-44.
[43]	Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-1273.
[44]	Boomershine CS. Pregabalin for the management of fibromyalgia syndrome. J Pain Res 2010; 3: 81-88.
[45]	Tremont-Lukats and Beckonja MC. (2000) Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000; 60 (5): 1029-1052.
[46]	Binder MR. Gabapentin—the popular but controversial anticonvulsant drug may be zeroing in on the pathophysiology of disease. AJCEM 2021; 9 (4): 122-134.
[47]	Ferreira, MAR, O’Donovan MC, Sklar P. (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40 (9): 1056-1058.
[48]	Nieratschker V, Brückmann C, Plewnia C. CACNA1C risk variant affects facial emotion recognition in healthy individuals. Sci Rep 2015; 5: 17349
[49]	Yuan A, Yi Z, Wang Q, et al. ANK3 as a risk gene for schizophrenia: new data in Han Chinese and meta analysis. Am J Med Genet B Neuropsychiatr Genet 2012; 159B (8): 997-1005.
[50]	Lopez AY, Wang X, Xu M, et al. Ankyrin-G isoform imbalance and interneuronopathy link epilepsy and bipolar disorder. Mol Psychiatry 2017; 22 (10): 1464–1472.
[51]	Green EK, Grozeva D, Jones I, et al., Wellcome Trust Case Control Consortium, Holmans, PA, Owen, MJ, O'Donovan, MC, Craddock N. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 2010; 15 (10): 1016-1022.
[52]	Liu Y, Blackwood DH, Caesar S, et al. Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder. Mol Psychiatry 2011; 16 (1).
[53]	Iqbal Z, Vandeweyer G, van der Voet M, et al. Homozygous and heterozygous disruptions of ANK3: at the crossroads of neurodevelopmental and psychiatric disorders. Human Molecular Genetics 2013; 22: 1960-1970.
[54]	Subramanian J, Dye L, and Morozov, A. Rap1 signaling prevents L-type calcium channel-dependent neurotransmitter release. Journal of Neuroscience 2013; 33 (17): 7245.
[55]	Santos M, D'Amico D, Spadoni O, et al. Hippocampal hyperexcitability underlies enhanced fear memories in TgNTRK3, a panic disorder mouse model. Journal of Neuroscience 2013; 33 (38): 15259-15271.
[56]	Contractor A, Klyachko VA, Portera-Cailliau C. Altered neuronal and circuit excitability in Fragile X syndrome. Neuron 2015; 87 (4): 699-715.
[57]	O’Brien NL, Way MJ, Kandaswamy R, et al. The functional GRM3 Kozak sequence variant rs148754219 affects the risk of schizophrenia and alcohol dependence as well as bipolar disorder. Psychiatric Genetics 2014; 24: 277–278.
[58]	Schizophrenia Working Group of the Psychiatric Genomics Consortium: Ripke S, Neale BM, O’Donovan MC. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511 (7510): 421-427.
[59]	Freedman R, Coon H, Myles-Worsley M, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. PNAS 1997; 94 (2): 587–592.
[60]	Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast 2011; 1011: 157193.
[61]	Swanson OK, Maffei A. From hiring to firing: activation of inhibitory neurons and their recruitment in behavior. Front Mol Neurosci 2019.
[62]	Britton JW, Shih JJ. Antiepileptic drugs and suicidality. Drug, Healthcare and Patient Safety 2010; 2: 181-189.
[63]	Kahn DA, Sachs GS, Printz DJ, Carpenter D. Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. Journal of Psychiatric Practice 2000; 6 (4): 197-211.
[64]	Young LT. What is the best treatment for bipolar depression? J Psychiatry Neurosci 2008; 33 (6): 487-488.
[65]	Lubloy A, Kereszturi JL, Nemeth A, Mihalicza P. Exploring factors of diagnostic delay for patients with bipolar disorder: a population-based cohort study. BMC Psychiatry 2020; 20 (75).
[66]	Dagani J, Signorini G, Nielssen O, et al. Meta-Analysis of the Interval between the onset and management of bipolar disorder. The Canadian Journal of Psychiatry 2016; 64 (4).
[67]	Hirschfeld R, Lewis L, and Vornik L. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64 (2): 161-174.
[68]	Campbell D. People with bipolar disorder may wait 13 years for diagnosis. The Guardian 2012; https://www.theguardian.com/society/2012/jun/27/bipolar- disorder-diagnosis-survey. (Accessed 10/7/18).
[69]	Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003 Jan; 73 (1-2): 123-31.
[70]	Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rössler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 2003 Jan; 73 (1-2): 133-46.
[71]	Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL. Bipolar depression: overview and commentary. Harvard Review of Psychiatry 2010; 18 (3): 143-157.
[72]	Sultan RS, Correll CU, Schoenbaum M, et al. National patterns of commonly prescribed psychotropic medications to young people. J Child Adolesc Psychopharmacol 2018; 28 (3): 158-165.
[73]	Brody DJ, Gu Q. Antidepressant use among adults: United States, 2015-2018. National Center for Health Statistics. NCHS Data Brief No. 377, September 2020.
[74]	Chong Y, Fryar CD, Q. Prescription sleep aid use among adults: United States, 2005–2010. NCHS Data Brief. 127, August, 2013.
[75]	Cascade E, Kalali AH, Weisler RH. Varying uses of anticonvulsant medications. Psychiatry (Edgmont) 2008; 5 (6): 31-33.
[76]	Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 2012; 8: 186-212.
[77]	Seemüller F, Riedel M, Obermeier M, et al. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol 2009; 12 (2): 181-189.
[78]	Cherry D, Albert M, McCaig LF. Mental health-related physician office visits by adults aged 18 and over: United States, 2012-2014. NCHS Data Brief 2018; 311.
[79]	Binder MR. FLASH Syndrome: tapping into the root of chronic illness. AJCEM 2020; 8 (6): 101-109.
[80]	Lee DY, Kim E, Choi MH. Technical and clinical aspects of cortisol as a biochemical marker of chronic stress. BMB Rep 2015; 48 (4): 209–216.
[81]	Voineskos D, Daskalakas, ZJ, Blumberger, DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatric Disease and Treatment 2020; 16: 221-234.
[82]	Linda G. The biology of antidepressants. Ann Fam Med 2005; 3: 449-456.
[83]	Bowcut, JC and Weiser, M. Inflammation and Schizophrenia. Psychiatric Annals 2018; 48 (5): 237-243.
[84]	Boorman, E, Romano, GF, Russell, A, Mondelli, V, Pariante, CM. Are mood and anxiety disorders inflammatory diseases? Psychiatric Annals 2015; 45 (5): 240-248.
[85]	Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358 (1): 55-68.
[86]	Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry 2010; 9 (3): 165-161.
[87]	Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63 (8): 856-864.
[88]	Can AT, Hermens DF, Dutton M, et al. Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study. Transl Psychiatry 2021; 11 (101).
[89]	Irwin, S. A. et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med 2013; 16: 958–965.
[90]	Al Shirawi, M. I., Kennedy, S. H., Ho, K. T., Byrne, R. & Downar, J. Oral ketamine in treatment-resistant depression: a clinical effectiveness case series. J. Clin Psychopharmacol 2017; 37: 464–467.
[91]	Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry 2014; 76 (12): 970–976. doi: 10.1016/j.biopsych.2014.03.
[92]	Pribish A, Wood N, Kalava A. A Review of nonanesthetic uses of ketamine. Anesthesiol Res Pract 2020; 2020.

Cite This Article

Plain Text BibTeX RIS

APA Style

Michael Raymond Binder. (2021). Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future. American Journal of Clinical and Experimental Medicine, 9(5), 174-182. https://doi.org/10.11648/j.ajcem.20210905.18

Copy | Download

ACS Style

Michael Raymond Binder. Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future. Am. J. Clin. Exp. Med. 2021, 9(5), 174-182. doi: 10.11648/j.ajcem.20210905.18

Copy | Download

AMA Style

Michael Raymond Binder. Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future. Am J Clin Exp Med. 2021;9(5):174-182. doi: 10.11648/j.ajcem.20210905.18

Copy | Download

@article{10.11648/j.ajcem.20210905.18,
  author = {Michael Raymond Binder},
  title = {Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {9},
  number = {5},
  pages = {174-182},
  doi = {10.11648/j.ajcem.20210905.18},
  url = {https://doi.org/10.11648/j.ajcem.20210905.18},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20210905.18},
  abstract = {After more than a century of scientific study and philosophical debate, the neurobiology of psychiatric disorders is still unclear. However, an emerging hypothesis contends that psychiatric and related functional symptoms are rooted in an inherent hyperexcitability of the neurological system. Particularly under the influence of stress, too many neurons fire for too long, resulting in circuit-specific psychiatric symptoms such as anxiety, depression, irritability, insomnia, inattention, and obsessional thinking as well as various physical symptoms that have no identifiable organic cause, such as migraine headache, fibromyalgia, irritable bowel, and chronic pain. Based on this hypothesis, anticonvulsant drugs, which could more aptly be called “Neuroregulators” because of their proposed mechanism of action, should have emerged as the drugs of choice for most of these disorders. Yet the use of anticonvulsants, at least for psychiatric disorders, dwindles in comparison to antidepressants, antipsychotics, psychostimulants, and sedative hypnotics. This article addresses the dearth of anticonvulsant drug use and the hypothetical reasons that several other classes of drugs continue to be used ahead of anticonvulsants despite the expanding base of evidence in support of the neuronal hyperexcitability hypothesis. The article will also propose new ways that anticonvulsants could be used to optimize their effectiveness for the wide range of disorders they should be able to treat, and it will discuss the means by which anticonvulsants could, in theory, be used prophylactically to prevent the development of an equally wide range of general medical conditions, including diabetes, high blood pressure, cardiovascular disease, autoimmune disease, dementia, and cancer.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future
AU  - Michael Raymond Binder
Y1  - 2021/10/28
PY  - 2021
N1  - https://doi.org/10.11648/j.ajcem.20210905.18
DO  - 10.11648/j.ajcem.20210905.18
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 174
EP  - 182
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20210905.18
AB  - After more than a century of scientific study and philosophical debate, the neurobiology of psychiatric disorders is still unclear. However, an emerging hypothesis contends that psychiatric and related functional symptoms are rooted in an inherent hyperexcitability of the neurological system. Particularly under the influence of stress, too many neurons fire for too long, resulting in circuit-specific psychiatric symptoms such as anxiety, depression, irritability, insomnia, inattention, and obsessional thinking as well as various physical symptoms that have no identifiable organic cause, such as migraine headache, fibromyalgia, irritable bowel, and chronic pain. Based on this hypothesis, anticonvulsant drugs, which could more aptly be called “Neuroregulators” because of their proposed mechanism of action, should have emerged as the drugs of choice for most of these disorders. Yet the use of anticonvulsants, at least for psychiatric disorders, dwindles in comparison to antidepressants, antipsychotics, psychostimulants, and sedative hypnotics. This article addresses the dearth of anticonvulsant drug use and the hypothetical reasons that several other classes of drugs continue to be used ahead of anticonvulsants despite the expanding base of evidence in support of the neuronal hyperexcitability hypothesis. The article will also propose new ways that anticonvulsants could be used to optimize their effectiveness for the wide range of disorders they should be able to treat, and it will discuss the means by which anticonvulsants could, in theory, be used prophylactically to prevent the development of an equally wide range of general medical conditions, including diabetes, high blood pressure, cardiovascular disease, autoimmune disease, dementia, and cancer.
VL  - 9
IS  - 5
ER  -

Copy | Download

Author Information

Michael Raymond Binder

Department of Psychiatry, NorthShore University HealthSystem, Highland Park, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Michael Raymond Binder. (2021). Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future. American Journal of Clinical and Experimental Medicine, 9(5), 174-182. https://doi.org/10.11648/j.ajcem.20210905.18

Copy | Download

ACS Style

Michael Raymond Binder. Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future. Am. J. Clin. Exp. Med. 2021, 9(5), 174-182. doi: 10.11648/j.ajcem.20210905.18

Copy | Download

AMA Style

Michael Raymond Binder. Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future. Am J Clin Exp Med. 2021;9(5):174-182. doi: 10.11648/j.ajcem.20210905.18

Copy | Download

@article{10.11648/j.ajcem.20210905.18,
  author = {Michael Raymond Binder},
  title = {Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {9},
  number = {5},
  pages = {174-182},
  doi = {10.11648/j.ajcem.20210905.18},
  url = {https://doi.org/10.11648/j.ajcem.20210905.18},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20210905.18},
  abstract = {After more than a century of scientific study and philosophical debate, the neurobiology of psychiatric disorders is still unclear. However, an emerging hypothesis contends that psychiatric and related functional symptoms are rooted in an inherent hyperexcitability of the neurological system. Particularly under the influence of stress, too many neurons fire for too long, resulting in circuit-specific psychiatric symptoms such as anxiety, depression, irritability, insomnia, inattention, and obsessional thinking as well as various physical symptoms that have no identifiable organic cause, such as migraine headache, fibromyalgia, irritable bowel, and chronic pain. Based on this hypothesis, anticonvulsant drugs, which could more aptly be called “Neuroregulators” because of their proposed mechanism of action, should have emerged as the drugs of choice for most of these disorders. Yet the use of anticonvulsants, at least for psychiatric disorders, dwindles in comparison to antidepressants, antipsychotics, psychostimulants, and sedative hypnotics. This article addresses the dearth of anticonvulsant drug use and the hypothetical reasons that several other classes of drugs continue to be used ahead of anticonvulsants despite the expanding base of evidence in support of the neuronal hyperexcitability hypothesis. The article will also propose new ways that anticonvulsants could be used to optimize their effectiveness for the wide range of disorders they should be able to treat, and it will discuss the means by which anticonvulsants could, in theory, be used prophylactically to prevent the development of an equally wide range of general medical conditions, including diabetes, high blood pressure, cardiovascular disease, autoimmune disease, dementia, and cancer.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Anticonvulsants: The Psychotropic and Medically Protective Drugs of the Future
AU  - Michael Raymond Binder
Y1  - 2021/10/28
PY  - 2021
N1  - https://doi.org/10.11648/j.ajcem.20210905.18
DO  - 10.11648/j.ajcem.20210905.18
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 174
EP  - 182
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20210905.18
AB  - After more than a century of scientific study and philosophical debate, the neurobiology of psychiatric disorders is still unclear. However, an emerging hypothesis contends that psychiatric and related functional symptoms are rooted in an inherent hyperexcitability of the neurological system. Particularly under the influence of stress, too many neurons fire for too long, resulting in circuit-specific psychiatric symptoms such as anxiety, depression, irritability, insomnia, inattention, and obsessional thinking as well as various physical symptoms that have no identifiable organic cause, such as migraine headache, fibromyalgia, irritable bowel, and chronic pain. Based on this hypothesis, anticonvulsant drugs, which could more aptly be called “Neuroregulators” because of their proposed mechanism of action, should have emerged as the drugs of choice for most of these disorders. Yet the use of anticonvulsants, at least for psychiatric disorders, dwindles in comparison to antidepressants, antipsychotics, psychostimulants, and sedative hypnotics. This article addresses the dearth of anticonvulsant drug use and the hypothetical reasons that several other classes of drugs continue to be used ahead of anticonvulsants despite the expanding base of evidence in support of the neuronal hyperexcitability hypothesis. The article will also propose new ways that anticonvulsants could be used to optimize their effectiveness for the wide range of disorders they should be able to treat, and it will discuss the means by which anticonvulsants could, in theory, be used prophylactically to prevent the development of an equally wide range of general medical conditions, including diabetes, high blood pressure, cardiovascular disease, autoimmune disease, dementia, and cancer.
VL  - 9
IS  - 5
ER  -

Copy | Download